annb0t
Top 20
Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding 24-month results reinforced safety of treatment, with no serious treatment-related adverse effects related to HEMGENIX infusion HEMGENIX, recently approved by the U.S. Food and Drug Administration, is the first and only gene therapy for the treatment of certain adults living with hemophilia B
KING OF PRUSSIA, Pa., Dec....
>>> Read more: CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
KING OF PRUSSIA, Pa., Dec....
>>> Read more: CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
